

**Table 1. Overview of TEAEs and most common TEAEs (occurring in  $\geq 10\%$  of patients in any group; Safety Analysis Set)**

	Myoclonic seizures		Absence seizures	
	Placebo (n=23)	Perampanel (n=43)	Placebo (n=33)	Perampanel (n=39)
<b>TEAEs, n (%)</b>	18 (78.3)	36 (83.7)	25 (75.8)	34 (87.2)
<b>Treatment-related TEAEs, n (%)</b>	12 (52.2)	34 (79.1)	15 (45.5)	30 (76.9)
<b>Serious TEAEs, n (%)</b>	3 (13.0)	8 (18.6)	3 (9.1)	5 (12.8)
<b>TEAEs leading to discontinuation, n (%)</b>	1 (4.3)	4 (9.3)	2 (6.1)	5 (12.8)
<b>Most common (<math>\geq 10\%</math>) TEAEs, n (%)</b>				
Dizziness	2 (8.7)	9 (20.9)	3 (9.1)	11 (28.2)
Fatigue	1 (4.3)	9 (20.9)	3 (9.1)	9 (23.1)
Headache	3 (13.0)	5 (11.6)	5 (15.2)	5 (12.8)
Somnolence	1 (4.3)	5 (11.6)	3 (9.1)	6 (15.4)
Nasopharyngitis	3 (13.0)	3 (7.0)	3 (9.1)	5 (12.8)
Diarrhea	3 (13.0)	4 (9.3)	4 (12.1)	2 (5.1)
Vomiting	1 (4.3)	5 (11.6)	1 (3.0)	4 (10.3)
Contusion	1 (4.3)	3 (7.0)	3 (9.1)	4 (10.3)
Irritability	1 (4.3)	3 (7.0)	2 (6.1)	4 (10.3)
Weight increased	0 (0.0)	5 (11.6)	1 (3.0)	4 (10.3)

Patients with  $\geq 2$  TEAEs in the same system organ class (or with the same preferred term) are counted

only once for that system organ class (or preferred term)

TEAE, treatment-emergent adverse event